Ruth Peña Poderós
Ruth Peña obtained a degree in Biology from the University of Barcelona (UB) in 2001. After a year in the microbiology laboratory of the Hospital Sant Joan de Déu in Barcelona, she joined IrsiCaixa in May 2002. She worked in the immunopathogeny area as a member of Dr. Margarita Bofill’s group until June 2012, when she joined the Viral Immune Evasion and Vaccines (VIRIEVAC) group led by Dr. Julia Prado. She currently performs cell biology, immunology, molecular biology and analytical tasks for various projects.
Sirtuin-2, NAD-Dependent Deacetylase, Is a New Potential Therapeutic Target for HIV-1 Infection and HIV-Related Neurological Dysfunction.
Kinetics of immune responses elicited after three mRNA COVID-19 vaccine doses in predominantly antibody-deficient individuals.
Limited humoral and specific T-cell responses after SARS-CoV-2 vaccination in PLWH with poor immune reconstitution.
Nonhuman TRIM5 Variants Enhance Recognition of HIV-1-Infected Cells by CD8+ T Cells.
Restriction of HIV-1 replication in primary macrophages by IL-12 and IL-18 through the upregulation of SAMHD1.